Anavex Life Sciences Corp.
AVXL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$13,243 | -$11,196 | -$12,111 | -$11,620 |
| Dep. & Amort. | $0 | $0 | $0 | $0 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $4,324 | $1,449 | $2,055 | $2,013 |
| Change in WC | -$3,545 | $3,891 | -$2,064 | $2,890 |
| Other Non-Cash | $0 | $0 | $0 | $59 |
| Operating Cash Flow | -$12,464 | -$5,856 | -$12,120 | -$6,658 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | $0 | $0 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $0 | $0 | $0 | $0 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $119 | $852 | $708 | $89 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$2,262 | $0 | $0 | $4,195 |
| Financing Cash Flow | -$2,143 | $852 | $708 | $89 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$14,607 | -$5,004 | -$11,412 | -$6,569 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $115,771 | $120,775 | $132,187 | $138,756 |
| End Cash | $101,164 | $115,771 | $120,775 | $132,187 |
| Free Cash Flow | -$12,464 | -$5,856 | -$12,120 | -$6,658 |